Beijing Institute of Biotechnology Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02326194
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing Institute of Biotechnology

Active Ingredients

Drugs in Phase 3 Trials (1)

ad5-ncov (6 trials)

Drugs in Phase 2 Trials (2)

ebola vaccine (Ervebo) (1 trial)

recombinant novel coronavirus vaccine (adenovirus type 5 vector) (1 trial)

Drugs in Phase 1 Trials (1)

ad5-ebov (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhagic Fever, Ebola (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 4